Kestra Medical (KMTS) Q4 2026 Earnings Call Transcript
Kestra Medical (KMTS) discussed its FY26 results on an earnings call. Revenue was $95 million for the year, up 59% from FY25, and $28.6 million in Q4, up 66% year over year. Gross margin rose to 51.4% for FY26 (up about 11 pts). The company reported 6.3k prescriptions and expanding sales territories to about 130.
How this was made
The 30-second read
Why it matters
Investors can update models for revenue growth, gross margin expansion, and operating leverage based on the disclosed FY26 results and management’s stated margin outlook, which may influence valuation multiples and near-term expectations.
Market read
FY26 revenue growth (59% YoY) and gross margin expansion (to 51.4%) plus a stated path to 70%+ gross margins are the key decision inputs for KMTS positioning.
What to watch
The transcript emphasizes gross margin and prescriptions, but does not provide detailed cash flow, churn/retention, or reimbursement changes that could affect sustainability.
Background
The article is a transcript of Kestra Medical’s Q4 2026 earnings call, focused on ASSURE system adoption, WCD market underutilization, and FY26 financial performance.
Ticker impact
Kestra’s Q4 2026 earnings call transcript reports FY26 revenue of $95M (+59% YoY) and gross margin of 51.4% (+11 pts).
Moderately positive bias for KMTS as investors focus on operating leverage and margin trajectory.
The transcript includes multiple quantitative financial datapoints (revenue, growth, gross margin) and explicit margin guidance targets, which are actionable for positioning, though it is still a call transcript rather than a fresh filing/print.
Market effects
Supports the broader narrative that wearable cardiac monitoring/WCD adoption can drive unit economics and operating leverage.
No clear regional catalyst beyond US sales territory expansion.
Limited, as the discussion centers on US WCD market penetration and payer coverage.
Counterpoint
70%+ gross margin confidence may be challenged if device fleet growth and commercial expansion increase costs faster than revenue.
Key entities
- companyKestra Medical
ASSURE system provider discussed in the earnings call, reporting FY26 revenue growth and gross margin expansion.
- productASSURE
Cardiac recovery system described with clinical case examples and commercial adoption metrics.
- marketWCD market
Wearable cardioverter-defibrillator category discussed as underutilized and growing into a multibillion-dollar opportunity.
